| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1103220103 |
| P356 | DOI | 10.1038/S41598-018-24300-7 |
| P932 | PMC publication ID | 5895614 |
| P698 | PubMed publication ID | 29643378 |
| P50 | author | Kai-Lun Yu | Q88580531 |
| Chao-Chi Ho | Q57009805 | ||
| Jin-Yuan Shih | Q63654593 | ||
| P2093 | author name string | Ching-Kai Lin | |
| Chia-Lin Hsu | |||
| Tzu-Hsiu Tsai | |||
| Wei-Yu Liao | |||
| P2860 | cites work | Quantitative analysis of tumor in bronchial biopsy specimens | Q82748101 |
| Factors influencing visibility and diagnostic yield of transbronchial biopsy using endobronchial ultrasound in peripheral pulmonary lesions | Q84457082 | ||
| Endobronchial ultrasound-driven biopsy in the diagnosis of peripheral lung lesions | Q47686205 | ||
| Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy | Q47962291 | ||
| Diagnosis of peripheral pulmonary lesions using a bronchoscope insertion guidance system combined with endobronchial ultrasonography with a guide sheath. | Q50850773 | ||
| Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. | Q54268313 | ||
| RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer. | Q54577756 | ||
| Transbronchial lung biopsy: can specimen quality be predicted at the time of biopsy? | Q74469225 | ||
| Endobronchial ultrasound-guided transbronchial lung biopsy in solitary pulmonary nodules and peripheral lesions | Q78464814 | ||
| Multimodality bronchoscopic diagnosis of peripheral lung lesions: a randomized controlled trial | Q80019624 | ||
| Factors related to diagnostic yield of transbronchial biopsy using endobronchial ultrasonography with a guide sheath in small peripheral pulmonary lesions | Q80488095 | ||
| Endobronchial ultrasonography with guide-sheath for peripheral pulmonary lesions | Q80809685 | ||
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial | Q27851712 | ||
| Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial | Q27852787 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | Q28274882 | ||
| Intra-tumour heterogeneity: a looking glass for cancer? | Q29620149 | ||
| Radial probe endobronchial ultrasound for the diagnosis of peripheral lung cancer: systematic review and meta-analysis | Q33652284 | ||
| Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. | Q34116750 | ||
| Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular | Q34159011 | ||
| A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry | Q34405695 | ||
| Spatial and temporal diversity in genomic instability processes defines lung cancer evolution | Q34442770 | ||
| Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status | Q34473831 | ||
| Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence | Q34555510 | ||
| Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis | Q35360125 | ||
| Improved diagnostic yield of bronchoscopy in peripheral pulmonary lesions: combination of radial probe endobronchial ultrasound and rapid on-site evaluation | Q36427626 | ||
| EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer | Q37434212 | ||
| Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing | Q37832381 | ||
| Tissue sampling in lung cancer: a review in light of the MERIT experience | Q37887227 | ||
| Endobronchial ultrasound-guided transbronchial biopsy and brushing: a comparative evaluation for the diagnosis of peripheral pulmonary lesions | Q38146904 | ||
| Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/In | Q38259724 | ||
| Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer | Q39253416 | ||
| Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS. | Q39835396 | ||
| EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. | Q40324544 | ||
| Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern | Q46211832 | ||
| Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib | Q46504066 | ||
| Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib | Q46618741 | ||
| Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer | Q46694317 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5837 | |
| P577 | publication date | 2018-04-11 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer. | |
| P478 | volume | 8 |
| Q90042701 | Combination of electromagnetic navigation bronchoscopy-guided biopsy with a novel staining for peripheral pulmonary lesions |
| Q64134898 | Endoscopic Ultrasound with Bronchoscope-Guided Fine Needle Aspiration for the Diagnosis of Paraesophageally Located Lung Lesions |
| Q57020386 | Molecular analysis of peripheral lung adenocarcinoma in brush cytology obtained by EBUS plus fluoroscopy-guided bronchoscopy |
Search more.